@article{77dc0dedf5b749ba9810b632a713b9c6,
title = "Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial",
abstract = "There is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's disease.",
author = "S{\'e}verine Vermeire and Stefan Schreiber and Rubin, {David T.} and Geert D'Haens and Walter Reinisch and Mamoru Watanabe and Rajiv Mehta and Xavier Roblin and Ian Beales and Piotr Gietka and Toshifumi Hibi and Ihor Hospodarskyy and Timothy Ritter and Genovese, {Mark C.} and Paul Kwon and Eva Santermans and {Le Brun}, Franck-Olivier and Rahul Barron and Tomasz Masior and Silvio Danese",
note = "Acknowledgments: The DIVERSITY study was sponsored by Galapagos (Mechelen, Belgium) and Gilead Sciences (Foster City, CA, USA) was a collaborator for the study. ",
year = "2024",
month = dec,
day = "2",
doi = "10.1016/S2468-1253(24)00272-3",
language = "English",
volume = "10",
pages = "138--153",
journal = "The Lancet Gastroenterology & Hepatology",
issn = "2468-1253",
publisher = "Elsevier",
number = "2",
}